Abstract
Background
The aim of this paper was to study the evolution of primary Sjögren’s syndrome (pSS) immunological profile, its impact on pSS activity and long-term evolution in a bicentric cohort of French patients with pSS (n = 445, mean age 53.6 ± 14 years, mean follow-up 76.1 ± 51 months).
Methods
This is a retrospective cohort study.
Results
Two hundred twelve patients were Sjögren’s syndrome A (SSA) positive, and 131 were both SSA and Sjögren’s syndrome B (SSB) positive. Sixty-eight patients (15%) had cryoglobulinemia. Active systemic profile (i.e., hypergammaglobulinemia, rheumatoid factor (RF), and anti-Sjögren’s syndrome A (anti-SSA), anti-Sjögren’s syndrome B (anti-SSB) positivity), associated with multisystemic involvement, leads to an increased utilization of corticosteroid and hydroxychloroquine. Multivariate analysis pointed out independent statistical association between hypergammaglobulinemia, anti-SSA, anti-SSB, and RF. Cryoglobulinemia is associated with multi-systemic involvement, lymphoma, and pSS-related death.
Conclusion
The subset of patients with active immunological profile is characterized by systemic complications leading to immunosuppressive drug utilization and polyclonal B-cell activation profile.
Similar content being viewed by others
References
Fox RI, Stern M, Michelson P. Update in Sjögren syndrome. Curr Opin Rheumatol. 2000;12(5):391–8.
Alexander E, Arnett F, Provost T. Sjögren’s syndrome: association of anti-SSa antibodies with vasculitis, immunologic abnormalities and serologic hyperactivity. Ann Med Int. 1983;98:155–9.
Pease CT, Shattles W, Charles PJ, Venables PJ, Maini RN. Clinical, serological, and HLA phenotype subsets in Sjögren’s syndrome. Clin Exp Rheumatol. 1989;7(2):185–90.
Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. European study group on classification criteria for Sjögren’s syndrome. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American–European Consensus Group. Ann Rheum Dis. 2002;61(6):554–8.
Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J, et al. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore). 2008;87(4):210–9.
Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren’s syndrome. Arthritis Rheum. 2002;46(3):741–7.
Fauchais AL, Ouattara B, Gondran G, Lalloué F, Petit D, Ly K, et al. Articular manifestations in primary Sjögren syndrome: clinical significance and prognosis of 188 patients. Rheumatology (Oxford). 2010;49(6):1164–72.
Van Bijsterveld O. Diagnosis and differential diagnosis of keratoconjunctivitis sicca associated with tear gland degeneration. Clin Exp Rheumatol. 1990;8(5):3–6.
Schall G, Andferson L, Wolf R, Herdt J, Tarpley T, Cummings N, et al. Xerostomia in Sjögren’s syndrome. Evaluation by sequential salivary scintigraphy. JAMA. 1971;216:2109–16.
Chisholm D. Labial salivary gland biopsy in Sjögren’s disease. J Clin Pathol. 1968;21:656–60.
Asmussen K, Andersen V, Bendixen G, Schiodt M, Oxholm P. A new model for classification of disease manifestations in primary Sjögren’s syndrome: evaluation in a retrospective long-term study. J Intern Med. 1996;239(6):475–82.
Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM. Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore). 2009;88(5):284–93.
Muller K, Oxholm P, Mier-Madsen M, Wiik A. Circulating IgA- and IgM-rheumatoid factors in patients with primary Sjögren syndrome. Correlation to extraglandular manifestations. Scand J Rheumatol. 1989;18(1):29–31.
Fauchais A, Lambert M, Dubucquoi S, Hachulla E, Pasturel U, Queyrel V, et al. Inaugural Raynaud’s phenomemon is associated with a multisystemic involvement during follow up in primary Sjögren syndrome—A report of 162 patients. Int J Angiology. 2004;13(2):1061–711.
Garcia-Carrasco M, Ramos-Casals M, Rosas J, Pallares L, Calvo-Alen J, Cervera R, et al. Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore). 2002;81(4):270–80.
Ramos M, Cervera R, Garcia-Carrasco M, Miret C, Munoz FJ, Espinosa G, et al. Primary Sjögren’s syndrome: clinical and immunologic study of 80 patients. Med Clin (Barc). 1997;108(17):652–7.
Ramos-Casals M, Font J, Garcia-Carrasco M, Brito MP, Rosas J, Calvo-Alen J, et al. Primary Sjögren syndrome: hematologic patterns of disease expression. Medicine (Baltimore). 2002;81(4):281–92.
Ramos-Casals M, Anaya JM, Garcia-Carrasco M, Rosas J, Bove A, Claver G, et al. Cutaneous vasculitis in primary Sjögren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore). 2004;83(2):96–106.
Leone J, Pennaforte JL, Hamon R, Cleenewerck N, Vallerand H, Detree F, et al. Pulmonary manifestations of primary Gougerot-Sjögren syndrome. Apropos of 8 cases in a series of 35 patients. Rev Med Interne. 1996;17(4):291–9.
Zufferey P, Meyer OC, Grossin M, Kahn MF. Primary Sjögren’s syndrome (SS) and malignant lymphoma. A retrospective cohort study of 55 patients with SS. Scand J Rheumatol. 1995;24(6):342–5.
Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren’s syndrome. Arthritis Rheum. 1996;39(5):767–72.
Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006;65(6):796–803.
Voulgarelis M, Skopouli FN. Clinical, immunologic, and molecular factors predicting lymphoma development in Sjögren’s syndrome patients. Clin Rev Allergy Immunol. 2007;32(3):265–74.
Brito-Zeron P, Ramos-Casals M, Bove A, Sentis J, Font J. Predicting adverse outcomes in primary Sjögren’s syndrome: identification of prognostic factors. Rheumatology (Oxford). 2007;46(8):1359–62.
Mavragani CP, Tzioufas AG, Moutsopoulos HM. Sjögren’s syndrome: autoantibodies to cellular antigens. Clinical and molecular aspects. Int Arch Allergy Immunol. 2000;123(1):46–57.
Gottenberg JE, Busson M, Cohen-Solal J, Lavie F, Abbed K, Kimberly RP, et al. Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjögren’s syndrome. Ann Rheum Dis. 2005;64(7):1050–5.
Kelly CA, Foster H, Pal B, Gardiner P, Malcolm AJ, Charles P, et al. Primary Sjögren’s syndrome in north east England–a longitudinal study. Br J Rheumatol. 1991;30(6):437–42.
Davidson BK, Kelly CA, Griffiths ID. Primary Sjögren’s syndrome in the North East of England: a long-term follow-up study. Rheumatology (Oxford). 1999;38(3):245–53.
Cho CS, Park SH, Min JK, Lee SH, Kim HY. Clinical significances of antibodies to Ro/SS-A autoantigens and its subtypes in primary Sjögren’s syndrome. Korean J Intern Med. 1997;12(2):176–81.
Ichigawa Y, Takada M, Shimizu H, Uchiyama M, Motiushi J, Morita K. Clinical and immunological features of 106 patients with primary Sjögren’s syndrome: comparison of patients with and without other specific autoimmune disease or anti-SSa antibodies. Jap J of Rheum. 1993;4(3):153–64.
Haga HJ, Jonsson R. The influence of age on disease manifestations and serological characteristics in primary Sjögren’s syndrome. Scand J Rheumatol. 1999;28(4):227–32.
Ramos-Casals M, Cervera R, Font J, Garcia-Carrasco M, Espinosa G, Reino S, et al. Young onset of primary Sjögren’s syndrome: clinical and immunological characteristics. Lupus. 1998;7(3):202–6.
Acknowledgments
We thank Ms Lisa Mouche for the English correction of this manuscript.
Disclosure Statement
The authors have declared no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Martel, C., Gondran, G., Launay, D. et al. Active Immunological Profile Is Associated with Systemic Sjögren’s Syndrome. J Clin Immunol 31, 840–847 (2011). https://doi.org/10.1007/s10875-011-9553-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-011-9553-3